Andres Ordonez
Medical · Bakersfield, CANPI 1194835033
Payments from drug & device makers
Across 457 payments — averaging $32.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- Amgen$2K
- GSK$1K
- AbbVie$1K
- AstraZeneca$1K
- Lilly USA, LLC$757
- plus $5K from 38 others
What the payments were for
- Food & beverage$14,777100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,777 in reported general payments places this provider in the 95th percentile of 2,087 medical providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 203 | $166,502 |
| OzempicSemaglutide | 158 | $151,002 |
| FarxigaDapagliflozin Propanediol | 180 | $148,057 |
| ZenpepLipase/Protease/Amylase | 56 | $90,544 |
| RybelsusSemaglutide | 49 | $61,528 |
| ProliaDenosumab | 35 | $54,450 |
| CreonLipase/Protease/Amylase | 34 | $44,628 |
| TradjentaLinagliptin | 53 | $40,283 |
| JanuviaSitagliptin Phosphate | 44 | $39,987 |
| LinzessLinaclotide | 50 | $33,803 |
| EliquisApixaban | 32 | $24,314 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $22,065 |
| MyrbetriqMirabegron | 27 | $21,980 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 68 | $19,626 |
| TrulicityDulaglutide | 21 | $19,334 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy, Spiriva Respimat | $550 | $226,712286 claims |
| Novo NordiskOzempic, Rybelsus | $2,852 | $212,531207 claims |
| AstraZenecaFarxiga, Symbicort | $1,158 | $153,117203 claims |
| Aimmune Therapeutics, Inc.Zenpep | $532 | $90,54456 claims |
| AbbVieCreon, Linzess | $1,227 | $78,43184 claims |
| MerckJanuvia, Janumet | $206 | $58,09378 claims |
| AmgenProlia | $2,342 | $54,45035 claims |
| PfizerEliquis | $122 | $24,31432 claims |
| GSKTrelegy Ellipta | $1,495 | $22,06536 claims |
| Lilly USA, LLCTrulicity | $757 | $19,33421 claims |
| Johnson & JohnsonXarelto | $123 | $15,93120 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $58 | $8,78212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 medical providers in California.
Other medical in Bakersfield
- Geo MathewBakersfield$20K
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- David DoriguzziLancaster$514K
- Alison GracomIrvine$467K
- Jeffrey BonnaudLos Angeles$314K
- Ana TorresLaguna Beach$229K
- Heather ParlettRedlands$168K
- Deirdre MoxleyFullerton$149K
- Tri leGardena$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.